

**Comparison of vaccine-induced immune thrombocytopenia and thrombosis (VITT) cases  
following two adenovirus-vectored COVID-19 vaccines**

Rian Van Rampelbergh, Sue Pavord, Luis Anaya-Velarde, Vitalija van Paassen, Karin Hardt,  
Emiliano Tatar, Javier Ruiz-Guiñazú, Dawn Baumgardner, Valérie Oriol Mathieu, Nicolas Praet,  
Hendy Kristyanto, Jerald Sadoff, Macaya Douoguih, Yimei Xu, Frank Struyf

**SUPPLEMENT**

**List of tables**

Supplementary Table 1	Geographic distribution of patients with VITT after Ad26.COV2.S vaccination .....	2
Supplementary Table 2	Presenting symptoms in patients with VITT after Ad26.COV2.S vaccination .....	3
Supplementary Table 3	Treatments used in patients with VITT after COVID-19 vaccination according to vaccine type .....	4
Supplementary Table 4	Demographics, clinical characteristics, and laboratory findings in patients with definite/probable VITT after Ad26.COV2.S significantly related to outcome .....	5

**Supplementary Table 1                      Geographic distribution of patients with VITT after  
Ad26.COV2.S vaccination**

Characteristic	Ad26.COV2.S
	N=86 n (%)
Austria or Germany	6 (7.0)
Belgium	1 (1.2)
Brazil	2 (2.3)
Denmark	1 (1.2)
France	2 (2.3)
Greece	1 (1.2)
Italy	5 (5.8)
Poland	1 (1.2)
Portugal	2 (2.3)
Slovenia	2 (2.3)
South Africa	1 (1.2)
Spain	5 (5.8)
The Netherlands	3 (3.5)
US	49 (57.0)
Unknown (EU)	5 (5.8)
Total EU	34 (39.5)

VITT, vaccine-induced immune thrombocytopenia and thrombosis

**Supplementary Table 2**  
**vaccination**

**Presenting symptoms in patients with VITT after Ad26.COV2.S**

<b>Characteristic</b>	<b>Ad26.COV.2.S</b> <b>N=86</b> <b>n/N (%)*</b>
<b>General</b>	
Fever	17 / 61 (27.9)
Chills	11 / 61 (18.0)
Body aches	15 / 61 (24.6)
Myalgia	8 / 61 (13.1)
<b>Neurologic</b>	
Headache	42 / 70 (60.0)
Hemiparesis	12 / 61 (19.7)
Blurred vision	7 / 61 (11.5)
Diplopia	3 / 61 (4.9)
Seizures	8 / 62 (12.9)
Reduced consciousness	8 / 61 (13.1)
Aphasia	2 / 61 (3.3)
<b>Gastrointestinal</b>	
Nausea/Vomiting	24 / 62 (38.7)
Abdominal pain	17 / 61 (27.9)
<b>Respiratory</b>	
Chest pain	8 / 61 (13.1)
Dyspnoea	9 / 61 (14.8)
Haemoptysis	2 / 61 (3.3)
Cough	1 / 61 (1.6)
<b>Extremities</b>	
Extremity pain	14 / 61 (23.0)
Leg swelling	7 / 61 (11.5)
<b>Bleeding tendency</b>	
Bruising	5 / 61 (8.2)
Other	0 / 61

n/N, number of patients / number of patients with non-missing data

\*Percentage is calculated from the numbers of patients in each category for whom data were known.

**Supplementary Table 3                      Treatments used in patients with VITT after COVID-19  
vaccination according to vaccine type**

<b>Characteristic</b>	<b>Ad26.COV.2.S N=86 n/N (%)*</b>	<b>ChAdOx1 nCoV-19<sup>1</sup> N=220 n/N (%)*</b>
Non-heparin anticoagulant	43 / 52 (82.7)	150 / 220 (68)
Heparin	19 / 53 (35.8)	50 / 220 (23)
Intravenous Immunoglobulin	36 / 54 (66.7)	158 / 220 (72)
Corticosteroids	21 / 52 (40.4)	58 / 220 (26)
Platelet transfusion	5 / 51 (9.8)	30 / 220 (14)
Plasmapheresis	2 / 50 (4.0)	17 / 220 (8)
Thrombus removal (thrombectomy, thrombolysis, etc.)	17 / 52 (32.7)	32 / 220 (15)
Other treatment	0 / 50	-

n/N, number of patients / number of patients with non-missing data

\*Percentage is calculated from the numbers of patients in each category for whom data were known.

**Supplementary Table 4      Demographics, clinical characteristics, and laboratory findings in patients with definite/probable VITT after Ad26.COV2.S significantly related to outcome**

	<b>Fatal N=20</b>	<b>Outcome Non-fatal N=47</b>	<b>Unknown N=19</b>	<b>p-value*</b>
<b>Country</b>				
N	20	47	19	<0.0001
Austria	1 (5.0%)	1 (2.1%)	0	
Belgium	1 (5.0%)	0	0	
Brazil	2 (10.0%)	0	0	
Denmark	0	0	1 (5.3%)	
France	0	1 (2.1%)	1 (5.3%)	
Germany	3 (15.0%)	1 (2.1%)	0	
Greece	0	1 (2.1%)	0	
Italy	1 (5.0%)	1 (2.1%)	3 (15.8%)	
Poland	1 (5.0%)	0	0	
Portugal	2 (10.0%)	0	0	
Slovenia	1 (5.0%)	1 (2.1%)	0	
South Africa	0	1 (2.1%)	0	
Spain	3 (15.0%)	2 (4.3%)	0	
The Netherlands	0	3 (6.4%)	0	
USA	4 (20.0%)	33 (70.2%)	12 (63.2%)	
Unknown (EU)	1 (5.0%)	2 (4.3%)	2 (10.5%)	
<b>Secondary intracranial haemorrhage- no./total no. (%)</b>				
N	19	47	17	<0.05
Yes	10 (52.6%)	9 (19.1%)	1 (5.9%)	
No	9 (47.4%)	38 (80.9%)	16 (94.1%)	
Unknown	1	0	2	
<b>Platelet count, nadir (×10<sup>9</sup>/L)</b>				
N	20	47	19	<0.05
Mean	34.5	59.1	46.9	
95% CI	19.2; 49.7	46.7; 71.4	30.1; 63.8	
Median	27.0	58.0	32.0	
Range	(7.0; 135.0)	(6.0; 140.0)	(7.0; 135.0)	
IQ range	(12.5; 44.0)	(20.0; 91.0)	(18.0; 66.0)	

Percentage is calculated from the numbers of patients in each category for whom data were known.

\* p-values using t-test for continuous outcomes, Fisher exact test for categorical outcomes. Only known outcomes are included in testing

## References

1. Pavord, S., *et al.* Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. *N Engl J Med* **385**, 1680-1689 (2021).